GENBGenerate Biomedicines, Inc.Small cap · $1.83B
$14.28-0.31% · 2026-07-13 · EOD
64/100 composite
A transparent blend of the four reads below — each opens into the tool it comes from. Not advice.Quality—
margins & F-ScoreValue50
valuation vs its own rangeMomentum49
trend · price — 200-daySmart Money92
buying · 0 funds · 6P/0S insidersMixed trend
vs S&P 500+4.2%
6-mo excess Trailing performance1M +8.5%
3M +25.2%
6M —
YTD +12.9%
1Y —
Not enough profitable-period data to value GENB on earnings.
ROIC = NOPAT ÷ (debt + equity − cash), using an effective tax rate of ~21%. Annual figures from SEC XBRL.
Net buying6P / 0S insiders · 0 funds hold · 0 Congress buys
Recent insidersNally Michael · Chief Executive OfficerBUY$240,000
AFEYAN NOUBAR · DirectorBUY$75.0M
Mendillo Jane L · DirectorBUY$24,000
AFEYAN NOUBAR · DirectorBUY$75.0M
Fhealth · 5/100
May need capitalGoing-concern flagGoing-concern warning — auditor flagged substantial doubt
- ●Going-concern warning Auditor flagged substantial doubt about the company continuing for the next 12 months — a raise is usually required.
Educational tools — not financial advice. Fundamentals from SEC EDGAR (XBRL); prices are end-of-day (Databento). Scores are a transparent blend of the components shown, computed on our own data — a research aid, not a recommendation.